BiPAP无创呼吸机在慢性阻塞性肺疾病急性加重合并Ⅱ型呼吸衰竭患者中的应用效果<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2025.05.001

Abstract
Figure/Table
References (14)
Related Citation (15)

Download: PDF (1219 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the application of bilevel positive airway pressure(BiPAP) non-invasive ventilator in patients with chronic obstructive pulmonary disease (COPD) experiencing acute exacerbation and type Ⅱ respiratory failure. 【Methods】From January 2022 to June 2023, 84 patients with COPD experiencing acute exacerbation and type Ⅱ respiratory failure were selected and randomly divided into the control group (receiving conventional nasal cannula oxygen therapy) and the observation group (receiving BiPAP non-invasive ventilator treatment), with 42 patients in each group. The levels of pulmonary function indicators [first-second forced expiratory volume (FEV₁), forced vital capacity (FVC), peak expiratory flow rate (PEFR)], blood gas analysis indicators [arterial blood carbon dioxide partial pressure (PaCO₂), arterial blood oxygen partial pressure (PaO₂), arterial blood oxygen saturation (SaO₂)], and serum inflammatory factors [interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP)] before and after treatment, as well as the occurrence of adverse reactions, were compared between the two groups. 【Results】After treatment, the FEV₁, FVC, PEFR, PaO₂, and SaO₂ levels in the observation group were higher than those in the control group, while the PaCO₂ and IL-6, hs-CRP levels were lower than those in the control group (P<0.05). The total incidence of adverse reactions in the observation group was 9.52%, significantly lower than 26.19% in the control group, and the difference was statistically significant (P<0.05). 【Conclusion】Compared with conventional nasal cannula oxygen therapy, BiPAP non-invasive ventilator applied in patients with COPD experiencing acute exacerbation and type Ⅱ respiratory failure can more effectively improve the pulmonary function and blood gas indicators, reduce the levels of serum inflammatory factors, and the total incidence of adverse reactions, and has higher safety.

Key words： Pulmonary Disease, Chronic Obstructive Ventilators, Mechanical Respiratory Insufficiency

Received: 02 December 2024

PACS:

R563.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Xiao
	CHEN Gaoying
	SHANG Yan

Cite this article:

WANG Xiao,CHEN Gaoying,SHANG Yan. Application of BiPAP Non-Invasive Ventilator in COPD Patients with Acute Exacerbation and Type Ⅱ Respiratory Failure[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(5): 737-739.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.05.001 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I5/737

[1] 康秀华. 慢性阻塞性肺病合并Ⅱ型呼吸衰竭应用BIPAP呼吸机的护理研究[J].生命科学仪器,2022,20(z1):52.
[2] 邓丽娟,王洪州,张艳,等. 舒芬太尼联合右美托咪定对Ⅱ型呼吸衰竭机械通气患者镇痛镇静效果研究[J].中国现代医学杂志,2018,28(28):72-76.
[3] 袁广琴,林云霞,洪梅. BiPAP无创呼吸机不同供氧方式应用效果观察[J].现代科学仪器,2023,40(5):78-81.
[4] 慢性阻塞性肺疾病急性加重诊治专家组.慢性阻塞性肺疾病急性加重诊治中国专家共识[J].国际呼吸杂志,2017,37(14):1041.
[5] 孙金昊,刘玉芳,李香兰,等. 家庭无创通气在稳定期COPD合并Ⅱ型呼吸衰竭患者中的疗效评价[J].河北医药,2022,44(8):1172-1175.
[6] 徐亚琴,蔡珣,王圆圆. 经鼻高流量湿化氧疗与无创正压通气治疗AECOPD并发呼吸衰竭对血气分析指标及氧化应激的影响[J].海军医学杂志,2022,43(4):380-384.
[7] 陈贞,唐健雄,李绍春,等. 湿化高流量鼻导管吸氧与传统鼻导管吸氧治疗老年复杂腹壁疝术后低氧血症的临床疗效[J].中华消化外科杂志,2023,22(9):1086-1092.
[8] 陈林,罗善高,韦新理,等. BiPAP无创呼吸机在呼吸衰竭缓解期患者机械通气中的应用[J].中华保健医学杂志,2021,23(1):95-97.
[9] 朱梦莉,张婧,曾琼莉,等. BiPAP无创呼吸机在急诊慢阻肺合并Ⅱ型呼吸衰竭的应用及护理[J].现代科学仪器,2020(3):106-108.
[10] 张晓燕,焦兴爱,孙翔. 无创呼吸机联合安全护理对慢阻肺合并 Ⅱ型呼吸衰竭患者的影响[J].齐鲁护理杂志,2019,25(11):12-14.
[11] 任英杰,汪桂青,赵美英,等. BiPAP无创通气联合莫西沙星溶液雾化吸入治疗老年慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的疗效[J].中国老年学杂志,2022,42(21):5226-5228.
[12] 李宁,卢春兰,蒋碧佳,等. 经鼻高流量氧疗与无创正压通气治疗老年慢阻肺合并Ⅱ型呼吸衰竭的临床研究[J].川北医学院学报,2020,35(3):489-492.
[13] 罗明. 多沙普仑结合常规疗法治疗慢阻肺并发Ⅱ型呼吸衰竭的效果及对ACO₂、SLC16的影响[J].临床肺科杂志,2017,22(9):1595-1598.
[14] 冯骅,张重阳,王耀辉,等. 经鼻高流量氧疗治疗慢阻肺合并Ⅱ型呼吸衰竭的效果初探[J].生命科学仪器,2022,20(z1):229.